2 Pulmonary fibrosis was first described in the 1930's, and while its etiology has become 24 somewhat more clear in recent years, the disease remains virtually untreatable (1, 5) . The etiology of 25 pulmonary fibrosis has stirred considerable debate over the years. Initially, pulmonary fibrosis was 26 treated as an inflammatory disease. However, poor clinical response to anti-inflammatory therapy 27 made evident that the inflammatory responses seen in histological examination of biopsied fibrotic 28 tissue are "paraphenomena" (4). The more contemporary hypothesis is that progression of pulmonary 29 fibrosis is due to defects in organ repair processes and/or alterations in the intricate cell-cell signaling 30 events that mediate normal wound healing (3, 10). While debates have raged over the pathogenesis of 31 pulmonary fibrosis, all have agreed that new therapeutic approaches, preferably ones that target 32 multiple aspects of the disease, are clearly needed. 33
Pulmonary fibroblasts and alveolar epithelial cells play central roles in the formation and 34 maintenance of lung structure and function. Fibroblasts establish and maintain pulmonary architecture 35 through the synthesis of collagens and other extracellular matrix proteins. These cells are also 36 responsible for scar formation following tissue injury, as they migrate to sites of inflammation and 37 rapidly proliferate. Following lung injury, scar formation must eventually give way to regeneration of 38 normal alveolar structure, including the epithelial barrier. Dysregulated production of extracellular 39 matrix and persistent fibroblast proliferation and migration are hallmarks of pulmonary fibrosis. Thus, 40 impaired apoptotic responses and/or persistent activation signals in fibroblasts could interfere with 41 alveolar epithelial regeneration (healing) and alter alveolar structure and function. 42
Understanding the function and regulation of alveolar epithelial cells and fibroblasts, including 43 the origin of these latter cells during the injury/repair process, is key for developing therapeutic 44 strategies for treating pulmonary fibrosis. Much effort has focused on classical fibrogenic mediators, 45
including TGF-ß, TNFα, PDGF and others (10). These entities modulate wound repair processes such3 as immune cell invasion, epithelial-mesenchymal transition, differentiation of mesenchymal stem cells 47 and activation of fibroblasts (2, 12). While significant progress has been made in understanding these 48 processes, no effective treatment for pulmonary fibrosis has emerged. 49
More recently, the Wnt/ß-catenin signaling pathway has been studied as central to the wound 50 healing process. This pathway modulates activation and differentiation of fibroblasts as well as the 51 differentiation of alveolar epithelia from mesenchymal stem cells (9). In this issue of AJP Cell, Wang 52 and coworkers employ a Tankyrase inhibitor, XAV939, to suppress Wnt/ß-catenin signaling in mice 53 subjected to bleomycin-induced lung fibrosis. Tankyrase mediates poly-ADP-ribosylation of Axin2 to 54 facilitate Axin2 proteolysis, which leads to fewer ß-catenin degradative complexes and increased ß-55 catenin signaling (Figure 1 ). They observe increased survival and a significant reduction in lung 56 fibrosis, despite administering the therapy 10 days after induction of the fibrotic process with 57 bleomycin. Using cell culture studies, these investigators found that XAV939 treatment inhibited the 58 proliferation of fibroblasts and reduced their differentiation into activated myofibroblasts. Moreover,, 59
the authors found that this inhibitor promoted the differentiation of bone marrow-derived mesenchymal 60 stem cells into an epithelial-like phenotype when co-cultured with alveolar type II epithelial cells. 61
The study by Wang and co-workers, along with prior publications from this group and others 62 (6, 11, 13), makes clear that the Wnt/ß-catenin signaling pathway plays a major role in pulmonary 63 fibrosis. This pathway appears to affect two key cell types involved in lung injury and repair: it 64 activates fibroblast proliferation and inhibits mesenchymal stem cell differentiation into epithelia 65 (instead promoting differentiation into a fibroblast-like phenotype). Therefore, inhibition of Wnt/ß-66 catenin signaling gives a two-pronged effect in reversing pulmonary fibrosis (Figure 1 ). This feature 67 may prove to be critical, since other therapeutic approaches that target a single pathway have fallen 68 short in clinical trials of pulmonary fibrosis. Perhaps equally important, multiple druggable targets 69 4 exist in the Wnt/ß-catenin pathway (as evidenced by the different inhibitors used in this and other 70 studies). While targeting different aspects of the pathway may not prove to have equivalent effects, it 71 does spur optimism that an effective but tolerable therapy with a small molecule will emerge. 72
Many questions,though, remain unanswered. First, the authors use a co-culture approach to 73 demonstrate the effect of XAV939 on epithelial differentiation, so it is not certain that this process also 74 occurs in vivo. Future studies should seek to quantify the degree of epithelial differentiation that 75 occurs in this disease model and determine if inhibition of ß-catenin signaling has these same effects in 76 vivo. Second, while there is evidence that Wnt signaling is increased in humans with pulmonary 77 fibrosis (7), the degree to which the Wnt/ß-catenin pathway is dysregulated in the disease is not clear. in the setting of pulmonary fibrosis is two-pronged: it inhibits fibroblast activation (reducing 105 extracellular matrix production) and promotes mesenchymal stem cell differentiation into lung 106 epithelia (facilitating wound repair). 107 108
